U.S. stock night trading fluctuations: Haleon rose 7.53% in after-hours trading, optimistic earnings guidance and executive appointments boost market confidence

U.S. Stock Night Market Movements Haleon rose 7.53% in the night market. Based on recent key news: On April 29, Haleon reaffirmed its expectation of 3%-5% organic revenue growth for the full year of 2026 and anticipated high single-digit growth in adjusted operating profit. This optimistic financial guidance boosted market confidence and drove the stock price up. Source: Zhitong Finance On April 29, Haleon announced a 2.2% organic revenue growth in the first quarter, slightly below analysts' expectations of 2.3%. Nevertheless, growth in the North American market and strong performance in oral health products still had a positive impact on the company. Source: Dow Jones Newswires On April 27, Haleon appointed Richard Manso as Chief Marketing Officer for the U.S., aiming to drive data-driven, consumer-oriented marketing strategies. This personnel change is seen as part of the company's restructuring and growth strategy in the U.S. market, enhancing investor confidence in the company's future performance. Source: Haleon Company Announcement. Consumer brands face market challenges and need to pay attention to supply chain risks. Stocks with High Trading Volume in the Industry Eli Lilly rose 0.25% in the night market. Based on recent key news: On April 27, the prescription data for Eli Lilly's newly launched oral weight loss drug Foundayo in its early market performance was inferior to its competitor Novo Nordisk, leading to a nearly 4% drop in stock price. Novo Nordisk's oral weight loss drug Wegovy had significantly higher prescription volumes in its second week post-launch, affecting market confidence in Eli Lilly. On April 28, Eli Lilly partnered with NVIDIA to establish an innovation lab with an investment of $1 billion, aiming to leverage high-performance supercomputers to tackle challenges in the pharmaceutical industry. This move is seen as an important step to enhance the company's R&D capabilities, which may have a positive impact on long-term stock prices. On April 28, Morningstar analysts pointed out that pricing pressures and policy changes in the U.S. market could affect Eli Lilly's drug sales, but the pilot program launched by the Centers for Medicare & Medicaid Services is expected to expand insurance coverage for GLP-1 drugs, potentially providing upward space for stock prices. The pharmaceutical industry faces policy changes and market competition pressures. Novo Nordisk fell 0.77% in the night market. Based on recent key news: On April 28, the patent expiration of semaglutide will reshape the GLP-1 market landscape in China, and Novo Nordisk faces competition pressure from generic drugs. After the patent expires, generic drugs will enter the market after April 2027, affecting Novo Nordisk's market share. Source: Yaozhi Data On April 27, Eli Lilly's newly launched oral weight loss drug Foundayo performed poorly in its initial market phase, while Novo Nordisk's Wegovy had higher prescription volumes, driving up Novo Nordisk's stock price. The prescription volume of Eli Lilly's Foundayo in the U.S. market was inferior to that of Novo Nordisk, affecting the market competition landscape. Source: MoneyDJ News On April 29, Canada approved the generic version of Novo Nordisk's Ozempic, increasing market competition. The approval of the generic drug may lead to price pressure on Novo Nordisk in the Canadian market. Source: Reuters. The competition in the GLP-1 market is intensifying, and the impact of patent expirations is significant. Pfizer rose 0.11% in after-hours trading. Based on recent key news: On April 28, Pfizer reached a settlement agreement with three pharmaceutical manufacturers to extend the patent protection of Vyndamax until June 1, 2031. This move is expected to keep Pfizer's revenue stable in the mid-term from 2028 to 2031. On April 29, Jefferies raised Pfizer's target price from $34 to $35, reflecting market confidence in Pfizer's future performance. On April 28, Pfizer projected that its revenue would remain stable in the mid-term from 2028 to 2031, primarily due to the extension of patent protection for the Vyndamax drug. Pfizer's recent settlement agreement extends patent protection, stabilizing revenue expectations